Varian Medical Systems Invests in COTA, Inc. to Help Drive Faster, More Accurate Data-Driven Cancer Care
Varian has invested $20M in COTA. Together, the two companies will work to empower cancer clinics with curated RWD and analytics tools.
COTA Extends Research Collaboration Agreement With The U.S. Food and Drug Administration
COTA has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology.
COTA’s Podcast Brings Together RWD Experts from Across the Industry
Real World Talk with COTA brings together thought leaders across the industry to discuss RWD and its impact on drug development and cancer care. Meet some of our recent guests…